GM‐CSF as a therapeutic target in psoriasis: randomised, controlled investigation using namilumab – a specific, human anti‐GM‐CSF monoclonal antibody

British Journal of Dermatology, Volume 0, Issue ja, -Not available-.


https://ift.tt/2x5Bogu